XML 146 R100.htm IDEA: XBRL DOCUMENT v3.25.2
Moderna Collaboration and License Agreement - Narrative (Details)
$ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended
Feb. 28, 2025
item
Jun. 30, 2024
USD ($)
Jan. 31, 2022
USD ($)
product
item
Mar. 31, 2025
USD ($)
item
Mar. 31, 2024
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Moderna Collaboration and License Agreement              
Collaboration revenues       $ 3,700 $ 3,400 $ 19,600 $ 14,900
Collaboration revenues       3,729 $ 3,397 19,632 $ 14,919
Option Right Collaboration Revenues              
Moderna Collaboration and License Agreement              
Collaboration revenues           3,800  
Collaboration and License Agreement | Research and Development Services              
Moderna Collaboration and License Agreement              
Noncurrent portion of deferred revenue       41,300   41,300  
Moderna License Agreement | Research and Development Services              
Moderna Collaboration and License Agreement              
Collaboration revenues       42,400      
Collaboration revenues           38,700  
Moderna License Agreement | Option Right Collaboration Revenues              
Moderna Collaboration and License Agreement              
Collaboration revenues       3,800      
Moderna | Collaboration and License Agreement              
Moderna Collaboration and License Agreement              
Maximum of research targets | item     12        
Number of oncology research targets | item 12            
Number of oncology research targets, nominated | item 10            
Number of research targets, replacement nominations | item 4            
Number of oncology research targets, ceased development | item 2            
Number of nominated autoimmune target | item 2            
Moderna | Collaboration and License Agreement | Research and Development Services              
Moderna Collaboration and License Agreement              
Upfront non-refundable payment received     $ 45,000 $ 45,000   $ 45,000  
Number of potential products to develop and commercialize | product     12        
Number of performance obligations | item       2      
Moderna | Collaboration and License Agreement | Research and Development Services | Minimum              
Moderna Collaboration and License Agreement              
Amount receivable per product     $ 247,000        
Moderna | Collaboration and License Agreement | Research and Development Services | Maximum              
Moderna Collaboration and License Agreement              
Amount receivable per product     $ 253,000        
Moderna | Moderna License Agreement              
Moderna Collaboration and License Agreement              
Collaboration revenues   $ 2,000